Abdul Razak Mohamed Sikkander
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abdul Razak Mohamed Sikkander has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Sangeeta R Mishra
9 shared publicationsKhadeeja Yasmeen
8 shared publicationsK. Kavitha
7 shared publicationsManoharan Meena
Department of Chemistry, R.M.K. Engineering College, Kavaraipettai, Chennai-India
7 shared publicationsHala S. Abuelmakarem
Department of Biomedical Engineering, College of Engineering, King Faisal University, Al-Ahsa, 31982, Saudi Arabia
6 shared publications- Joel Jose Puga Coelho Rodrigues
Federal University of Piau (UFPI), Teresina - PI, Brazil
6 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Elsevier in In Silico Research in Biomedicine
- Vol. 2
Polypyrrole-doped MXene electrodes with AI-driven ferrocene redox cycling for ultrasensitive miRNA-155 quantification in ovarian cancer
- 21 September 2026
- Published by Elsevier in In Silico Research in Biomedicine
- Vol. 2
Open AccessPolypyrrole-doped MXene electrodes with AI-driven ferrocene redox cycling for ultrasensitive miRNA-155 quantification in ovarian cancer
- Open Access
- 17 December 2025
- Published by World Academic and Scientific Research Publication in World Journal of Multidisciplinary Studies
- Vol. 2 (12) , 39-45
Trustworthy and Transparent AI for Genomic Discovery
Artificial intelligence (AI), particularly deep learning, has demonstrated remarkable ability to analyze genomic data, uncover patterns, predict disease associations, and infer regulatory mechanisms. Despite high predictive performance, these models often function as "black boxes," limiting interpretability and trust in biological insights derived from them. Developing methods to interpret AI models trained on genomic data is crucial for biological discovery, clinical translation, and ethical deployment. This paper explores approaches for interpretable AI in genomics, including feature attribution, saliency mapping, attention mechanisms, model distillation, and explainable graph-based models. We demonstrate a framework combining convolutional neural networks (CNNs), transformer-based architectures, and gradient-based attribution methods to identify genomic features that drive model predictions. A hypothetical benchmarking dataset evaluates interpretability techniques on tasks such as predicting gene expression, regulatory element activity, and variant pathogenicity. Results show that integrated interpretation pipelines enhance transparency by highlighting biologically meaningful motifs, regulatory regions, and variant effects, with tabulated comparisons of feature importance and predictive accuracy. We discuss challenges such as handling long genomic sequences, integrating multi-omic data, avoiding spurious correlations, and balancing model performance with interpretability. Future perspectives include development of standardized interpretability metrics, integration of multi-scale genomic features, and creation of interpretable AI platforms for clinical genomics. In conclusion, interpretable AI methods are essential to bridge predictive power and biological insight, enabling responsible use of AI for genomic research, precision medicine, and genome editing.
- 17 December 2025
- Published by World Academic and Scientific Research Publication in World Journal of Multidisciplinary Studies
- Vol. 2 (12) , 39-45
Open AccessTrustworthy and Transparent AI for Genomic Discovery
Artificial intelligence (AI), particularly deep learning, has demonstrated remarkable ability to analyze genomic data, uncover patterns, predict disease associations, and infer regulatory mechanisms. Despite high predictive performance, these models often function as "black boxes," limiting interpretability and trust in biological insights derived from them. Developing methods to interpret AI models trained on genomic data is crucial for biological discovery, clinical translation, and ethical deployment. This paper explores approaches for interpretable AI in genomics, including feature attribution, saliency mapping, attention mechanisms, model distillation, and explainable graph-based models. We demonstrate a framework combining convolutional neural networks (CNNs), transformer-based architectures, and gradient-based attribution methods to identify genomic features that drive model predictions. A hypothetical benchmarking dataset evaluates interpretability techniques on tasks such as predicting gene expression, regulatory element activity, and variant pathogenicity. Results show that integrated interpretation pipelines enhance transparency by highlighting biologically meaningful motifs, regulatory regions, and variant effects, with tabulated comparisons of feature importance and predictive accuracy. We discuss challenges such as handling long genomic sequences, integrating multi-omic data, avoiding spurious correlations, and balancing model performance with interpretability. Future perspectives include development of standardized interpretability metrics, integration of multi-scale genomic features, and creation of interpretable AI platforms for clinical genomics. In conclusion, interpretable AI methods are essential to bridge predictive power and biological insight, enabling responsible use of AI for genomic research, precision medicine, and genome editing.
- Open Access
- 17 December 2025
- Published by World Academic and Scientific Research Publication in World Journal of Multidisciplinary Studies
- Vol. 2 (12) , 46-53
AI-powered generative frameworks for the rational design of synthetic genomes and next-generation cellular architectures
The engineering of synthetic genomes—complete or partial genome constructs designed de novo or heavily modified—represents a frontier in synthetic biology with vast potential for biotechnology, medicine, agriculture and basic science. However, traditional synthetic genome design remains highly labor-intensive, reliant on manual annotation, iterative assembly and trial‑and‑error testing of large sequence spaces. Artificial intelligence (AI) offers a transformative opportunity to augment and accelerate synthetic genome design by learning patterns of genomic architecture, regulatory logic and functional outcomes. In this paper, we explore the development of AI‑based methodologies for designing and engineering synthetic genomes. We propose a workflow integrating generative models (e.g., language‑model architectures trained on genome sequences), predictive deep learning for functional annotation, and optimization algorithms for minimal genome design, modular genome construction and error‑correction. To illustrate potential benefit, we present a hypothetical benchmarking study in which an AI‑augmented design workflow reduced design cycles by ~40 %, increased predicted functional genomic modules by ~30 %, and lowered predicted assembly error rate by ~25 % compared to manual design. Tabulated results highlight comparisons across methods. We discuss methodological elements including feature encoding (e.g., genomic motifs, regulatory elements, three‑dimensional chromatin structure), model architectures (transformer‑based sequence models, graph neural networks for genome assembly graphs), training/validation workflows, and deployment considerations (interpretability, biosafety, ethical oversight). Key challenges include limited training data for synthetic genomes, ensuring viability of AI‑designed genomes in living systems, and governance of biosecurity risks. Looking forward, we delineate future perspectives: foundation‑models for synthetic life, closed‑loop design‑build‑test‑learn pipelines with AI, and integration of synthetic genomes into programmable cellular factories. In conclusion, AI‑driven design and engineering of synthetic genomes provides a promising paradigm to accelerate synthetic biology, but must be advanced with rigorous experimental validation, robust modelling and responsible stewardship.
- 17 December 2025
- Published by World Academic and Scientific Research Publication in World Journal of Multidisciplinary Studies
- Vol. 2 (12) , 46-53
Open AccessAI-powered generative frameworks for the rational design of synthetic genomes and next-generation cellular architectures
The engineering of synthetic genomes—complete or partial genome constructs designed de novo or heavily modified—represents a frontier in synthetic biology with vast potential for biotechnology, medicine, agriculture and basic science. However, traditional synthetic genome design remains highly labor-intensive, reliant on manual annotation, iterative assembly and trial‑and‑error testing of large sequence spaces. Artificial intelligence (AI) offers a transformative opportunity to augment and accelerate synthetic genome design by learning patterns of genomic architecture, regulatory logic and functional outcomes. In this paper, we explore the development of AI‑based methodologies for designing and engineering synthetic genomes. We propose a workflow integrating generative models (e.g., language‑model architectures trained on genome sequences), predictive deep learning for functional annotation, and optimization algorithms for minimal genome design, modular genome construction and error‑correction. To illustrate potential benefit, we present a hypothetical benchmarking study in which an AI‑augmented design workflow reduced design cycles by ~40 %, increased predicted functional genomic modules by ~30 %, and lowered predicted assembly error rate by ~25 % compared to manual design. Tabulated results highlight comparisons across methods. We discuss methodological elements including feature encoding (e.g., genomic motifs, regulatory elements, three‑dimensional chromatin structure), model architectures (transformer‑based sequence models, graph neural networks for genome assembly graphs), training/validation workflows, and deployment considerations (interpretability, biosafety, ethical oversight). Key challenges include limited training data for synthetic genomes, ensuring viability of AI‑designed genomes in living systems, and governance of biosecurity risks. Looking forward, we delineate future perspectives: foundation‑models for synthetic life, closed‑loop design‑build‑test‑learn pipelines with AI, and integration of synthetic genomes into programmable cellular factories. In conclusion, AI‑driven design and engineering of synthetic genomes provides a promising paradigm to accelerate synthetic biology, but must be advanced with rigorous experimental validation, robust modelling and responsible stewardship.
- Open Access
- 17 December 2025
- Published by World Academic and Scientific Research Publication in World Journal of Multidisciplinary Studies
- Vol. 2 (12) , 31-38
Intelligent Visualization Frameworks Driven by AI for Multi-Dimensional Genomic Data Exploration and Interpretation
In the era of high‑throughput sequencing and multi‑omics profiling, the volume and complexity of genomic data pose significant challenges for researchers seeking to generate actionable insights. Traditional static visualization tools often fail to accommodate the scale, heterogeneity, and dimensionality of modern genomic datasets. Artificial intelligence (AI) offers transformative potential for advanced visualization: interactive, adaptive, and insight‑driven tools that support exploration, pattern detection and hypothesis generation. This paper presents a comprehensive framework for developing AI‑powered visualization systems tailored to genomic data workflows. We describe key components including data ingestion, feature embedding, dimensionality reduction, graph‑neural network-based layout generation, and interactive UI modules. A prototype application was evaluated on three use‑cases: whole‑genome variant distributions (n = 2,000 samples), transcriptome‑variant integration (n = 500), and 3D chromatin interaction visualization (Hi‑C data, n = 50). The AI‑augmented visualizations enabled users to identify sub‑population clusters 30 % faster than baseline tools, and to detect rare variant hotspots previously overlooked in manual reviews. We discuss challenges such as model interpretability, user‑interface design, real‑time interaction at scale, and dataset bias. Finally, we outline future directions including self‑supervised visualization embedding, immersive VR/AR genomics dashboards, federated collaborative visualization and deployment in clinical genomics settings. In conclusion, AI‑powered visualization tools hold the promise to democratize access to complex genomic data, accelerate discovery and enhance the interpretability of large‑scale genomics studies—provided that rigorous design, user‑centered workflows and open standards are embraced.
- 17 December 2025
- Published by World Academic and Scientific Research Publication in World Journal of Multidisciplinary Studies
- Vol. 2 (12) , 31-38
Open AccessIntelligent Visualization Frameworks Driven by AI for Multi-Dimensional Genomic Data Exploration and Interpretation
In the era of high‑throughput sequencing and multi‑omics profiling, the volume and complexity of genomic data pose significant challenges for researchers seeking to generate actionable insights. Traditional static visualization tools often fail to accommodate the scale, heterogeneity, and dimensionality of modern genomic datasets. Artificial intelligence (AI) offers transformative potential for advanced visualization: interactive, adaptive, and insight‑driven tools that support exploration, pattern detection and hypothesis generation. This paper presents a comprehensive framework for developing AI‑powered visualization systems tailored to genomic data workflows. We describe key components including data ingestion, feature embedding, dimensionality reduction, graph‑neural network-based layout generation, and interactive UI modules. A prototype application was evaluated on three use‑cases: whole‑genome variant distributions (n = 2,000 samples), transcriptome‑variant integration (n = 500), and 3D chromatin interaction visualization (Hi‑C data, n = 50). The AI‑augmented visualizations enabled users to identify sub‑population clusters 30 % faster than baseline tools, and to detect rare variant hotspots previously overlooked in manual reviews. We discuss challenges such as model interpretability, user‑interface design, real‑time interaction at scale, and dataset bias. Finally, we outline future directions including self‑supervised visualization embedding, immersive VR/AR genomics dashboards, federated collaborative visualization and deployment in clinical genomics settings. In conclusion, AI‑powered visualization tools hold the promise to democratize access to complex genomic data, accelerate discovery and enhance the interpretability of large‑scale genomics studies—provided that rigorous design, user‑centered workflows and open standards are embraced.
- Open Access
- 14 December 2025
- Published by World Academic and Scientific Research Publication in World Journal of Applied Medical Sciences
- Vol. 2 (12) , 31-39
Leveraging artificial intelligence to integrate genomics, transcriptomics, and proteomics data for enhanced disease prediction
The rapid expansion of high‑throughput sequencing and mass‑spectrometry technologies has given rise to vast amounts of genomics, transcriptomics and proteomics data—offering unprecedented insight into biological systems. However, analysing each data type in isolation often fails to capture the cross‑layer complexity of gene regulatory networks, post‑translational modifications and phenotypic manifestations. To address this gap, artificial intelligence (AI) algorithms—particularly supervised machine learning, deep neural networks and multimodal fusion models—are increasingly employed to integrate multiple “‑omics” layers for systems‑level insight. In this paper, we examine the development and deployment of AI‑based pipelines that combine genomic sequence/variant data, RNA expression profiles and proteomic abundance measurements. We outline key methodological steps: data preprocessing and normalization, feature engineering across omics, architecture choices (e.g., autoencoders, graph neural networks, attention‑based fusion), training and validation workflows. A hypothetical benchmarking dataset (n = 500 patients, three omics layers) illustrates how a multimodal fusion model improved disease classification accuracy (AUC ~ 0.92) versus single‑omics models (~ 0.83), and revealed novel cross‑layer biomarkers. We discuss advantages (higher predictive power, ability to discover cross‑layer signatures), as well as challenges: data heterogeneity, missing modality data, interpretability, and generalisability across cohorts. Finally, future perspectives are presented: self‑supervised foundation models across omics, federated learning for privacy‑sensitive data, and explainable AI (XAI) to enhance clinical trust. In conclusion, the integration of genomics, transcriptomics and proteomics via AI holds strong promise for deeper mechanistic insight and precision medicine—but realising that promise depends on methodological rigor, interpretability and equitable representation of diverse populations.
- 14 December 2025
- Published by World Academic and Scientific Research Publication in World Journal of Applied Medical Sciences
- Vol. 2 (12) , 31-39
Open AccessLeveraging artificial intelligence to integrate genomics, transcriptomics, and proteomics data for enhanced disease prediction
The rapid expansion of high‑throughput sequencing and mass‑spectrometry technologies has given rise to vast amounts of genomics, transcriptomics and proteomics data—offering unprecedented insight into biological systems. However, analysing each data type in isolation often fails to capture the cross‑layer complexity of gene regulatory networks, post‑translational modifications and phenotypic manifestations. To address this gap, artificial intelligence (AI) algorithms—particularly supervised machine learning, deep neural networks and multimodal fusion models—are increasingly employed to integrate multiple “‑omics” layers for systems‑level insight. In this paper, we examine the development and deployment of AI‑based pipelines that combine genomic sequence/variant data, RNA expression profiles and proteomic abundance measurements. We outline key methodological steps: data preprocessing and normalization, feature engineering across omics, architecture choices (e.g., autoencoders, graph neural networks, attention‑based fusion), training and validation workflows. A hypothetical benchmarking dataset (n = 500 patients, three omics layers) illustrates how a multimodal fusion model improved disease classification accuracy (AUC ~ 0.92) versus single‑omics models (~ 0.83), and revealed novel cross‑layer biomarkers. We discuss advantages (higher predictive power, ability to discover cross‑layer signatures), as well as challenges: data heterogeneity, missing modality data, interpretability, and generalisability across cohorts. Finally, future perspectives are presented: self‑supervised foundation models across omics, federated learning for privacy‑sensitive data, and explainable AI (XAI) to enhance clinical trust. In conclusion, the integration of genomics, transcriptomics and proteomics via AI holds strong promise for deeper mechanistic insight and precision medicine—but realising that promise depends on methodological rigor, interpretability and equitable representation of diverse populations.
- Open Access
- 14 December 2025
- Published by World Academic and Scientific Research Publication in World Journal of Applied Medical Sciences
- Vol. 2 (12) , 24-30
Federated Correction of Batch Effects & Heterogeneity in Single-cell and Multi-omics Genomics (privacy-preserving)
The rapid proliferation of genomic data from large‑scale sequencing initiatives presents unprecedented opportunities for precision medicine, population genomics and biotechnology. However, the sensitive nature of genomic information—uniquely identifying, immutable and deeply personal—poses critical security and privacy challenges. Traditional methods of data protection (anonymisation, access control) are increasingly inadequate in the face of advanced attacks (membership inference, model inversion) and large‑scale AI analysis. This paper explores the development of artificial intelligence (AI)‑based methods to secure genomic data throughout its lifecycle: from storage and sharing to analysis and model training. We review technical approaches including federated learning, homomorphic encryption, secure multi‑party computation, differential privacy and generative synthetic‑data modelling, each designed to mitigate risk while enabling genomic‑AI workflows. We present a hypothetical benchmarking study where a federated‑learning pipeline augmented with differential‑privacy noise and encrypted aggregation reduced membership inference risk by ~45 % compared with naïve central models, while retaining >90 % of predictive utility. Tabulated results demonstrate trade‑offs between utility, latency and privacy budget. We discuss key methodological details—feature extraction, model architecture, privacy budget calibration—and highlight deployment considerations: interpretability, regulatory compliance (GDPR, HIPAA), adversarial threats and quantum‑resistant cryptography. Future perspectives emphasise hybrid AI‑cryptography frameworks, standardised privacy metrics for genomics, and governance models embedding privacy‑by‑design. In conclusion, AI‑based security methods are critical enablers for responsible genomic‑AI research and clinical translation, offering a path toward privacy‑preserving genomics at scale.
- 14 December 2025
- Published by World Academic and Scientific Research Publication in World Journal of Applied Medical Sciences
- Vol. 2 (12) , 24-30
Open AccessFederated Correction of Batch Effects & Heterogeneity in Single-cell and Multi-omics Genomics (privacy-preserving)
The rapid proliferation of genomic data from large‑scale sequencing initiatives presents unprecedented opportunities for precision medicine, population genomics and biotechnology. However, the sensitive nature of genomic information—uniquely identifying, immutable and deeply personal—poses critical security and privacy challenges. Traditional methods of data protection (anonymisation, access control) are increasingly inadequate in the face of advanced attacks (membership inference, model inversion) and large‑scale AI analysis. This paper explores the development of artificial intelligence (AI)‑based methods to secure genomic data throughout its lifecycle: from storage and sharing to analysis and model training. We review technical approaches including federated learning, homomorphic encryption, secure multi‑party computation, differential privacy and generative synthetic‑data modelling, each designed to mitigate risk while enabling genomic‑AI workflows. We present a hypothetical benchmarking study where a federated‑learning pipeline augmented with differential‑privacy noise and encrypted aggregation reduced membership inference risk by ~45 % compared with naïve central models, while retaining >90 % of predictive utility. Tabulated results demonstrate trade‑offs between utility, latency and privacy budget. We discuss key methodological details—feature extraction, model architecture, privacy budget calibration—and highlight deployment considerations: interpretability, regulatory compliance (GDPR, HIPAA), adversarial threats and quantum‑resistant cryptography. Future perspectives emphasise hybrid AI‑cryptography frameworks, standardised privacy metrics for genomics, and governance models embedding privacy‑by‑design. In conclusion, AI‑based security methods are critical enablers for responsible genomic‑AI research and clinical translation, offering a path toward privacy‑preserving genomics at scale.
- Open Access
- 14 December 2025
- Published by World Academic and Scientific Research Publication in World Journal of Applied Medical Sciences
- Vol. 2 (12) , 14-23
AI-Driven Genomic Biomarker Discovery for Precision Diagnosis and Personalized Treatment
The identification of genomic biomarkers has become a cornerstone for precision medicine, enabling early disease diagnosis, prognosis prediction, and personalized treatment strategies. Recent advances in artificial intelligence (AI), including machine learning (ML) and deep learning (DL), have demonstrated substantial potential in analyzing high-dimensional genomic datasets to uncover novel biomarkers. AI algorithms can integrate heterogeneous data types, such as gene expression, single nucleotide polymorphisms (SNPs), and epigenetic modifications, to identify patterns associated with specific diseases. This study reviews current methodologies and applications of AI in genomic biomarker discovery, highlighting successes in oncology, cardiovascular disorders, and neurodegenerative diseases. Key AI approaches, including random forests, support vector machines, convolutional neural networks, and autoencoders, are employed to improve predictive accuracy and reduce false discovery rates. The study also discusses challenges, such as data sparsity, interpretability, and computational resource requirements. Additionally, we examine case studies where AI-driven genomic biomarker identification has guided targeted therapy selection, improving patient outcomes. Finally, we outline future perspectives, emphasizing the integration of multi-omics data, real-time clinical data streams, and federated learning to enhance biomarker discovery across diverse populations. Overall, AI-driven genomic biomarker research holds transformative potential for accelerating personalized medicine, optimizing therapeutic interventions, and providing actionable insights into disease mechanisms.
- 14 December 2025
- Published by World Academic and Scientific Research Publication in World Journal of Applied Medical Sciences
- Vol. 2 (12) , 14-23
Open AccessAI-Driven Genomic Biomarker Discovery for Precision Diagnosis and Personalized Treatment
The identification of genomic biomarkers has become a cornerstone for precision medicine, enabling early disease diagnosis, prognosis prediction, and personalized treatment strategies. Recent advances in artificial intelligence (AI), including machine learning (ML) and deep learning (DL), have demonstrated substantial potential in analyzing high-dimensional genomic datasets to uncover novel biomarkers. AI algorithms can integrate heterogeneous data types, such as gene expression, single nucleotide polymorphisms (SNPs), and epigenetic modifications, to identify patterns associated with specific diseases. This study reviews current methodologies and applications of AI in genomic biomarker discovery, highlighting successes in oncology, cardiovascular disorders, and neurodegenerative diseases. Key AI approaches, including random forests, support vector machines, convolutional neural networks, and autoencoders, are employed to improve predictive accuracy and reduce false discovery rates. The study also discusses challenges, such as data sparsity, interpretability, and computational resource requirements. Additionally, we examine case studies where AI-driven genomic biomarker identification has guided targeted therapy selection, improving patient outcomes. Finally, we outline future perspectives, emphasizing the integration of multi-omics data, real-time clinical data streams, and federated learning to enhance biomarker discovery across diverse populations. Overall, AI-driven genomic biomarker research holds transformative potential for accelerating personalized medicine, optimizing therapeutic interventions, and providing actionable insights into disease mechanisms.
- 17 June 2025
- Published by National Taiwan University in Biomedical Engineering: Applications, Basis and Communications
- Vol. 38 (01)
ORGANOMETALLIC COMPOUND’S PHOTOTOXICITY AGAINST CANCER CELLS
Organometallic compounds have recently emerged as a hot topic in the field of cancer research owing to their unorthodox and promising therapeutic potential. One attractive development project is their phototoxicity for targeted cancer therapy. In general, these materials consist of metal-to-ligand charge transfer sensitizers and hence display very different photochemical properties than ordinary organic molecules. Objectives: In the current study, we evaluated whether organometallic compounds are appropriate to become novel photodynamic agents for photocytotoxic activity. Methods: A variety of organometallic compounds were synthesized and characterized. In vitro phototoxicity of these compounds was evaluated on various cancer cell lines. This includes measuring cell viability, apoptosis, and reactive oxygen species (ROS) generation after exposure to compounds in the presence of light at specific wavelengths. Conclusion: Many of the organometallic compounds examined were quite phototoxic when activated with light. The toxicity changed depending on the metal center and the nature of ligands (organic). These compounds increased ROS production and tumor cell apoptosis. Comparative studies demonstrated that certain organometallic compounds exhibited higher activity against cancer cells than the currently used photodynamic therapy (PDT) agents. Organometallic compounds can be considered strong phototoxic agents for more evolved PDT. When exposed to light, these chemicals selectively injure cancer cells and thus may provide more effective therapeutic options with fewer side effects than existing treatments. Nevertheless, more complete research is required to fine-tune such compounds and elucidate the precise mechanisms of action. The hallmarks of photodynamic anticancer effects triggered by organometallic compounds and various forms in which they gain access to the target cells are presented here.
- 17 June 2025
- Published by National Taiwan University in Biomedical Engineering: Applications, Basis and Communications
- Vol. 38 (01)
ORGANOMETALLIC COMPOUND’S PHOTOTOXICITY AGAINST CANCER CELLS
Organometallic compounds have recently emerged as a hot topic in the field of cancer research owing to their unorthodox and promising therapeutic potential. One attractive development project is their phototoxicity for targeted cancer therapy. In general, these materials consist of metal-to-ligand charge transfer sensitizers and hence display very different photochemical properties than ordinary organic molecules. Objectives: In the current study, we evaluated whether organometallic compounds are appropriate to become novel photodynamic agents for photocytotoxic activity. Methods: A variety of organometallic compounds were synthesized and characterized. In vitro phototoxicity of these compounds was evaluated on various cancer cell lines. This includes measuring cell viability, apoptosis, and reactive oxygen species (ROS) generation after exposure to compounds in the presence of light at specific wavelengths. Conclusion: Many of the organometallic compounds examined were quite phototoxic when activated with light. The toxicity changed depending on the metal center and the nature of ligands (organic). These compounds increased ROS production and tumor cell apoptosis. Comparative studies demonstrated that certain organometallic compounds exhibited higher activity against cancer cells than the currently used photodynamic therapy (PDT) agents. Organometallic compounds can be considered strong phototoxic agents for more evolved PDT. When exposed to light, these chemicals selectively injure cancer cells and thus may provide more effective therapeutic options with fewer side effects than existing treatments. Nevertheless, more complete research is required to fine-tune such compounds and elucidate the precise mechanisms of action. The hallmarks of photodynamic anticancer effects triggered by organometallic compounds and various forms in which they gain access to the target cells are presented here.
- 1 October 2024
- Published by National Taiwan University in Biomedical Engineering: Applications, Basis and Communications
- Vol. 37 (01)
RUTHENIUM ORGANOMETALLIC COMPOUNDS IN CANCER TREATMENT
Organometallic complexes with ruthenium have shown promise as potential anticancer agents. These complexes represent a class of compounds that can exhibit unique mechanisms of action, and they may offer advantages or overcome some limitations associated with platinum-based drugs, such as cisplatin. Ruthenium-based complexes can have diverse mechanisms of action. They may interact with DNA, proteins, or other cellular components, leading to cytotoxic effects on cancer cells. The versatility of ruthenium coordination chemistry allows for the design of complexes with specific properties. Some cancers that become resistant to platinum-based drugs may still respond to ruthenium-based compounds. This reduced cross-resistance is attributed to differences in the mechanisms of action between platinum and ruthenium complexes. Researchers can design ruthenium complexes to target specific cellular pathways or processes associated with cancer. This targeted approach aims to enhance the selectivity of the treatment for cancer cells while minimizing the impact on normal cells. Ruthenium complexes often have unique structural features that contribute to their stability and reactivity. These features can be tailored to optimize the pharmacological properties of the compounds. Ruthenium-based complexes may be explored in combination with other anticancer agents to achieve synergistic effects and enhance overall treatment efficacy. Ongoing research continues to explore the potential of ruthenium-based organometallic complexes, and preclinical studies have demonstrated promising results. As with any emerging field, further investigations and clinical trials are needed to fully understand the therapeutic potential and safety profiles of these compounds for various types of cancers.
- 1 October 2024
- Published by National Taiwan University in Biomedical Engineering: Applications, Basis and Communications
- Vol. 37 (01)
RUTHENIUM ORGANOMETALLIC COMPOUNDS IN CANCER TREATMENT
Organometallic complexes with ruthenium have shown promise as potential anticancer agents. These complexes represent a class of compounds that can exhibit unique mechanisms of action, and they may offer advantages or overcome some limitations associated with platinum-based drugs, such as cisplatin. Ruthenium-based complexes can have diverse mechanisms of action. They may interact with DNA, proteins, or other cellular components, leading to cytotoxic effects on cancer cells. The versatility of ruthenium coordination chemistry allows for the design of complexes with specific properties. Some cancers that become resistant to platinum-based drugs may still respond to ruthenium-based compounds. This reduced cross-resistance is attributed to differences in the mechanisms of action between platinum and ruthenium complexes. Researchers can design ruthenium complexes to target specific cellular pathways or processes associated with cancer. This targeted approach aims to enhance the selectivity of the treatment for cancer cells while minimizing the impact on normal cells. Ruthenium complexes often have unique structural features that contribute to their stability and reactivity. These features can be tailored to optimize the pharmacological properties of the compounds. Ruthenium-based complexes may be explored in combination with other anticancer agents to achieve synergistic effects and enhance overall treatment efficacy. Ongoing research continues to explore the potential of ruthenium-based organometallic complexes, and preclinical studies have demonstrated promising results. As with any emerging field, further investigations and clinical trials are needed to fully understand the therapeutic potential and safety profiles of these compounds for various types of cancers.
- Open Access
- 26 August 2024
- Published by Springer Nature in Research Square
Diagnosing Skin Cancer Using Shearlet Transform Multiresolution Computation
Skin cancer diagnosis relies on the accurate analysis of medical images to identify malignant and benign lesions. The Shearlet transform, a powerful mathematical tool for multiresolution analysis, has shown promise in enhancing the detection and classification of skin cancer. This study investigates the application of Shearlet transform-based multiresolution analysis in skin cancer diagnosis. The Shearlet transform, known for its ability to capture anisotropic features and directional information, provides a comprehensive representation of skin lesion images at multiple scales and orientations. We integrate the Shearlet transform with advanced image processing techniques to extract discriminative features from dermoscopic images. These features are then utilized to train a machine learning classifier, specifically a support vector machine (SVM), to distinguish between malignant and benign skin lesions. The proposed methodology is evaluated on a publicly available dataset, and the results demonstrate significant improvements in diagnostic accuracy compared to traditional methods. Our approach enhances feature extraction capabilities, leading to more reliable and precise skin cancer diagnosis, ultimately contributing to better patient outcomes.
- 26 August 2024
- Published by Springer Nature in Research Square
Open AccessDiagnosing Skin Cancer Using Shearlet Transform Multiresolution Computation
Skin cancer diagnosis relies on the accurate analysis of medical images to identify malignant and benign lesions. The Shearlet transform, a powerful mathematical tool for multiresolution analysis, has shown promise in enhancing the detection and classification of skin cancer. This study investigates the application of Shearlet transform-based multiresolution analysis in skin cancer diagnosis. The Shearlet transform, known for its ability to capture anisotropic features and directional information, provides a comprehensive representation of skin lesion images at multiple scales and orientations. We integrate the Shearlet transform with advanced image processing techniques to extract discriminative features from dermoscopic images. These features are then utilized to train a machine learning classifier, specifically a support vector machine (SVM), to distinguish between malignant and benign skin lesions. The proposed methodology is evaluated on a publicly available dataset, and the results demonstrate significant improvements in diagnostic accuracy compared to traditional methods. Our approach enhances feature extraction capabilities, leading to more reliable and precise skin cancer diagnosis, ultimately contributing to better patient outcomes.